HT
RVMD icon

Headlands Technologies’s Revolution Medicines RVMD Stock Holding History

Headlands Technologies’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,276
Closed -$1.49M – 951
2026
Q1 		$1.49M Sell
15,276
-11,999
-44% -$1.21M 0.17% 129
2025
Q4 		$2.17M Sell
27,275
-9,925
-27% -$651K 0.18% 123
2025
Q3 		$1.74M Buy
37,200
+26,938
+263% +$1.05M 0.14% 163
2025
Q2 		$378K Sell
10,262
-2,376
-19% -$91.3K 0.05% 368
2025
Q1 		$447K Buy
12,638
+4,320
+52% +$175K 0.05% 308
2024
Q4 		$364K Sell
8,318
-8,124
-49% -$410K 0.04% 407
2024
Q3 		$746K Buy
+16,442
New +$716K 0.09% 250
2024
Q2 		– Sell
-1,513
Closed -$48.8K – 1543
2024
Q1 		$48.8K Buy
1,513
+885
+141% +$26.2K 0.01% 722
2023
Q4 		$18K Buy
+628
New +$15.1K 0.01% 682

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Headlands Technologies's RVMD Position: Q2 2026 in Review

Headlands Technologies sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 15,276 shares — an estimated $1.49M sold.

Headlands Technologies first reported a position in RVMD in Q4 2023 and held it in 9 quarters. The position peaked at $2.17M in Q4 2025. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Headlands Technologies reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 15,276 Revolution Medicines shares in Q2 2026, an estimated $1.49M.
  • Headlands Technologies first reported a position in Revolution Medicines in Q4 2023 and held it in 9 quarters.
  • Headlands Technologies's Revolution Medicines position peaked at $2.17M in Q4 2025.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.